All In Biotech

Drug Trial Radar · NCT05792917

Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers

Bioequivalence Study of Tafolecimab Injections Manufactured by Two Different Processes in Chinese Healthy Male Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 166 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

166

Actual

Start

Mar 6, 2023

Primary completion

Mar 26, 2023

Study completion Aug 4, 2023

Sponsor

Sponsor type
Industry
First posted
Mar 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial is conducted in China. The purpose of this study is to evaluate the pharmacokinetic similarity of Tafolecimab with different manufacturing process in healthy male subjects. Another purpose is to determine safety, and immunogenicity of sintilimab with different manufacturing process,also to determine Pharmacodynamics of Tafolecimab with different manufacturing process

Conditions

  • Healthy Male Subjects

Interventions

  • tafolecimab (a modified manufacturing process)Drug

    450mg,SC,single dose

  • tafolecimab (a original manufacturing process)Drug

    450mg,SC,single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bioequivalence results using the peak serum drug concentration (Cmax) as the judging indicatorsTime frame: up to Day 57
  2. Bioequivalence results using the area under the serum concentration-time curve (AUC0-inf) as the judging indicatorsTime frame: up to Day 57

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aerospace Center Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.